DM1
MCID: MYT021
MIFTS: 63

Myotonic Dystrophy 1 (DM1) malady

Categories: Genetic diseases, Rare diseases, Neuronal diseases, Eye diseases, Reproductive diseases, Endocrine diseases, Muscle diseases

Aliases & Classifications for Myotonic Dystrophy 1

About this section
Sources:
11Disease Ontology, 12diseasecard, 13DISEASES, 23GeneReviews, 24GeneTests, 27GTR, 30ICD10, 31ICD10 via Orphanet, 32ICD9CM, 35LifeMap Discovery®, 37MedGen, 39MeSH, 40MESH via Orphanet, 45NCIt, 48NIH Rare Diseases, 50Novoseek, 52OMIM, 54Orphanet, 62SNOMED-CT, 64The Human Phenotype Ontology, 68UMLS, 69UMLS via Orphanet, 70UniProtKB/Swiss-Prot
See all MalaCards sources

Aliases & Descriptions for Myotonic Dystrophy 1:

Name: Myotonic Dystrophy 1 52 70 12 35 68
Myotonic Dystrophy Type 1 11 23 48 24 54 13
Steinert Myotonic Dystrophy 48 54 70 27
Steinert Disease 11 48 54 70
Dm1 48 24 54 70
Congenital Myotonic Dystrophy 11 48 68
Steinert's Disease 23 48 24
Dystrophia Myotonica 11 70
 
Myotonic Dystrophy 39 68
Myotonic Muscular Dystrophy Type 1 24
Myotonic Dystrophy of Steinert 11
Myotonic Dystrophy Congenital 50
Dystrophia Myotonica Type 1 48
Dystrophia Myotonica 1 70
Md1 54
Dm 70

Characteristics:

Orphanet epidemiological data:

54
myotonic dystrophy type 1:
Inheritance: Autosomal dominant; Prevalence: 1-9/100000 (Europe),1-5/10000 (United Kingdom),1-5/10000 (Iceland),1-9/100000 (Serbia),1-9/100000 (Japan),1-9/1000000 (Taiwan, Province of China),1-5/10000 (South Africa),6-9/10000,>1/1000,1-9/1000000 (Serbia),1-9/100000 (Italy),1-5/10000 (Ireland),1-5/10000,1-9/100000,1-5/10000 (Croatia); Age of onset: Adult,Neonatal; Age of death: any age

HPO:

64
myotonic dystrophy 1:
Inheritance: autosomal dominant inheritance

GeneReviews:

23
Penetrance: penetrance is high (nearly 100% by age 50 years) when all manifestations of the disease, even those that are subtle, are sought. however, mild cases (e.g., persons with only cataracts) may be missed [moxley & meola 2008]...


Classifications:



External Ids:

OMIM52 160900
Disease Ontology11 DOID:11722
ICD1030 G71.11
ICD9CM32 359.21
MeSH39 D009223
NCIt45 C84914
Orphanet54 ORPHA273
MESH via Orphanet40 C538008
UMLS via Orphanet69 C2931688
ICD10 via Orphanet31 G71.1

Summaries for Myotonic Dystrophy 1

About this section
OMIM:52 Myotonic dystrophy is an autosomal dominant disorder characterized mainly by myotonia, muscular dystrophy, cataracts,... (160900) more...

MalaCards based summary: Myotonic Dystrophy 1, also known as myotonic dystrophy type 1, is related to myotonic dystrophy 2 and dermatomyositis, and has symptoms including excessive daytime somnolence, weakness and Array. An important gene associated with Myotonic Dystrophy 1 is DMPK (Dystrophia Myotonica Protein Kinase), and among its related pathways are Aldosterone-regulated sodium reabsorption and miRs in Muscle Cell Differentiation. Affiliated tissues include skeletal muscle, heart and eye, and related mouse phenotype muscle.

Disease Ontology:11 A myotonic disease that is characterized by progressive muscle wasting and weakness affecting the distal skeletal and smooth muscles of lower legs, hands, neck, and face along with myotonia and cataracts and has physical basis in the autosomal dominant inheritance of the DMPK gene containing an expansion of a CTG trinucleotide repeat in the non-coding region.

NIH Rare Diseases:48 Myotonic dystrophy type 1 (md1), one of the two types of myotonic dystrophy, is an inherited type of muscular dystrophy that affects the muscles and other body systems (e.g., heart, eyes, endocrine system, and central nervous system). md1 has three forms that somewhat overlap: the mild form, classic form, and congenital form (present at birth). the mild form has the least severe symptoms of the different forms of md1 and is associated with a normal life span. the classic form is characterized by muscle weakness and wasting, prolonged muscle tensing (myotonia), cataract, and often, abnormal heart function. adults with the classic form may become physically disabled and may have a shortened life span. the congenital form is characterized by severe generalized weakness at birth (hypotonia), often causing complications with breathing and early death. md1 is inherited in an autosomal dominant manner and is caused by mutations in the dmpk gene. treatment is based on the signs and symptoms present. last updated: 5/19/2017

UniProtKB/Swiss-Prot:70 Dystrophia myotonica 1: A muscular disorder characterized by myotonia, muscle wasting in the distal extremities, cataract, hypogonadism, defective endocrine functions, male baldness and cardiac arrhythmias.

GeneReviews for NBK1165

Related Diseases for Myotonic Dystrophy 1

About this section

Graphical network of the top 20 diseases related to Myotonic Dystrophy 1:



Diseases related to myotonic dystrophy 1

Symptoms & Phenotypes for Myotonic Dystrophy 1

About this section

Symptoms by clinical synopsis from OMIM:

160900

Clinical features from OMIM:

160900

Human phenotypes related to Myotonic Dystrophy 1:

 54 64 (show all 38)
id Description HPO Frequency Orphanet Frequency HPO Source Accession
1 cryptorchidism64 54 Occasional (29-5%) HP:0000028
2 testicular atrophy64 54 Frequent (79-30%) HP:0000029
3 hydrocephalus64 54 Occasional (29-5%) HP:0000238
4 mask-like facies64 54 Very frequent (99-80%) HP:0000298
5 strabismus64 54 Occasional (29-5%) HP:0000486
6 cataract64 54 Frequent (79-30%) HP:0000518
7 abnormality of the endocrine system64 54 Frequent (79-30%) HP:0000818
8 muscular hypotonia64 54 Frequent (79-30%) HP:0001252
9 hypertonia64 54 Very frequent (99-80%) HP:0001276
10 respiratory distress64 54 Frequent (79-30%) HP:0002098
11 myotonia64 54 Very frequent (99-80%) HP:0002486
12 malformation of the heart and great vessels54 Frequent (79-30%)
13 hip dislocation64 54 Occasional (29-5%) HP:0002827
14 skeletal muscle atrophy64 54 Very frequent (99-80%) HP:0003202
15 emg abnormality64 54 Very frequent (99-80%) HP:0003457
16 hernia of the abdominal wall64 54 Occasional (29-5%) HP:0004299
17 intellectual disability, progressive64 54 Frequent (79-30%) HP:0006887
18 facial palsy64 54 Frequent (79-30%) HP:0010628
19 intellectual disability, severe64 54 Very frequent (99-80%) HP:0010864
20 abnormality of the upper urinary tract64 54 Occasional (29-5%) HP:0010935
21 abnormal hair quantity64 54 Frequent (79-30%) HP:0011362
22 first degree atrioventricular block64 54 Very frequent (99-80%) HP:0011705
23 non-midline cleft lip64 54 Occasional (29-5%) HP:0100335
24 hypogonadism64 HP:0000135
25 cholelithiasis64 HP:0001081
26 muscle weakness64 HP:0001324
27 facial diplegia64 HP:0001349
28 decreased fetal movement64 HP:0001558
29 polyhydramnios64 HP:0001561
30 dysphagia64 HP:0002015
31 cerebral atrophy64 HP:0002059
32 excessive daytime sleepiness64 HP:0002189
33 frontal balding64 HP:0002292
34 atrial flutter64 HP:0004749
35 atrial fibrillation64 HP:0005110
36 obsessive-compulsive trait64 HP:0008770
37 feeding difficulties in infancy64 HP:0008872
38 abnormality of cardiovascular system morphology64 HP:0030680

UMLS symptoms related to Myotonic Dystrophy 1:


excessive daytime somnolence, weakness

MGI Mouse Phenotypes related to Myotonic Dystrophy 1 according to GeneCards Suite gene sharing:

41
idDescriptionMGI Source AccessionScoreTop Affiliating Genes
1MP:00053697.7ATP2A1, CLCN1, DHCR7, DMPK, MBNL1, PRKCA

Drugs & Therapeutics for Myotonic Dystrophy 1

About this section

Drugs for Myotonic Dystrophy 1 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50)    (show all 140)
idNameStatusPhaseClinical TrialsCas NumberPubChem Id
1
Trastuzumabapproved, investigationalPhase 3, Phase 2, Phase 1784180288-69-19903
Synonyms:
180288-69-1
Anti HER2
Anti-erbB2 Monoclonal Antibody
D03257
HER2 Monoclonal Antibody
Herceptin
 
Herceptin (TN)
Ig gamma-1 chain C region
Trastuzumab
Trastuzumab (INN)
Trastuzumab (genetical recombination)
Trastuzumab (genetical recombination) (JAN)
trastuzumab
2
PertuzumabapprovedPhase 3, Phase 1, Phase 2127145040-37-5, 380610-27-52540
Synonyms:
2C4 Antibody
380610-27-5
D05446
Immunoglobulin G1, anti-(human v (receptor)) (human-mouse monoclonal 2C4 heavy chain), disulfide with human-mouse monoclonal 2C4 kappa-chain, dimer
LS-185920
MOAB 2C4
MOAB2C4
Monoclonal Antibody 2C4
 
Omnitarg
Perjeta
Pertuzumab
Pertuzumab (USAN/INN)
Pertuzumab (genetical recombination)
Pertuzumab (genetical recombination) (JAN)
pertuzumab
rhuMAb 2C4
rhuMAb-2C4
3
Paclitaxelapproved, vet_approvedPhase 3, Phase 2, Phase 1286433069-62-436314
Synonyms:
(2AR-(2aalpha,4beta,4abeta,6beta,9alpha(alpha r*,betas*),11alpha,12alpha,12balpha))-beta-(benzoylamino)-alpha-hydroxybenzenepropanoic acid 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester
12-benzoate, 9-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
157069-30-2
33069-62-4
5beta,20-Epoxy-1,2-alpha,4,7beta,10beta,13alpha-hexahydroxytax-11-en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
7,11-Methano-1H-cyclodeca[3,4]benz[1,2-b]oxete, benzenepropanoic acid deriv.
7,11-Methano-5H-cyclodeca[3,4]benz[1,2-b]oxete,benzenepropanoic acid deriv.
7-Epi-Paclitaxel
7-Epi-Taxol
7-Epipaclitaxel
7-Epitaxol
7-epi-Paclitaxel
7-epi-Taxol
AB00513812
ABI 007
ABI-007
ABI007
AC-675
AC1L1IOG
AC1L1VJI
AC1L9AVF
ACon1_002231
ANX-513
Abraxane
Abraxane (TN)
Abraxane I.V. Suspension
Abraxis BioScience brand of albumin-bound paclitaxel
Ambotz33069-62-4
Anzatax
Asotax
BIDD:PXR0046
BMS 181339-01
BMS-181339
BMS-181339-01
BPBio1_000320
BRD-A23723433-001-01-2
BRD-A28746609-001-04-0
BRD-K62008436-001-03-1
BSPBio_000290
BSPBio_001152
BSPBio_002614
Bio-0076
Bio1_000362
Bio1_000851
Bio1_001340
Bio2_000416
Bio2_000896
Bristaxol
C07394
C466458
C47H51NO14
CCRIS 8143
CHEBI:103439
CHEBI:45863
CHEMBL100910
CHEMBL418410
CHEMBL48
CID36314
CID441276
CID4666
CID6713921
CID6915727
CPD-8718
Capxol
D00491
DB01229
DHP-107
DHP-208
DRG-0190
DTS-301
DivK1c_000441
EU-0101201
Ebetaxel
EmPAC
Epitaxol
Genaxol
Genetaxyl
Genexol
Genexol-PM
HMS1362J13
HMS1568O12
HMS1792J13
HMS1922K08
HMS1990J13
HMS2090D07
HMS2093K15
HMS501G03
HSDB 6839
I06-0014
IDI1_000441
IDI1_002171
Intaxel
KBio1_000441
KBio2_000492
KBio2_002016
KBio2_002509
KBio2_003060
KBio2_004584
KBio2_005077
KBio2_005628
KBio2_007152
KBio2_007645
KBio3_000903
KBio3_000904
KBio3_001834
KBio3_002987
KBioGR_000492
KBioGR_001893
 
KBioGR_002509
KBioSS_000492
KBioSS_002016
KBioSS_002517
LMPR0104390001
LS-31070
LipoPac
Lopac0_001201
MBT 0206
MEGxp0_001940
MLS000863266
MLS001077297
MLS002154218
MLS002172439
MLS002695976
MPI-5018
Micellar Paclitaxel
Mitotax
MolPort-001-742-627
MolPort-003-665-783
MolPort-003-932-365
NCGC00024995-02
NCGC00024995-03
NCGC00024995-04
NCGC00024995-05
NCGC00024995-06
NCGC00024995-07
NCGC00164367-01
NCGC00164367-02
NCGC00164367-03
NCI60_000601
NINDS_000441
NK 105
NP-010981
NSC 125973
NSC-125973
NSC125973
NSC358882
Nanotaxel
Neuro_000060
Nova-12005
OAS-PAC-100
OncoGel
Onxal
Onxol
Onxol, Taxol, Nov-Onxol, Paclitaxel
P1632
Paclical
Pacligel
Paclitaxel
Paclitaxel (JAN/USP)
Paclitaxel (JAN/USP/INN)
Paclitaxel (Taxol)
Paclitaxel [USAN:INN:BAN]
Paxceed
Paxene
Paxoral
Plaxicel
Praxel
Prestwick0_000155
Prestwick1_000155
Prestwick2_000155
Prestwick3_000155
Probes2_000350
QW 8184
S-8184 Paclitaxel Injectable Emulsion
S1150_Selleck
SDCCGMLS-0066823.P001
SDP-013
SMP1_000228
SMR000394086
SMR000857385
SPBio_000943
SPBio_002229
SPECTRUM1503908
ST50306996
Spectrum2_000872
Spectrum3_001057
Spectrum4_001197
Spectrum5_001491
Spectrum_001536
T 7402
T1912_SIGMA
T7191_SIGMA
T7402_SIGMA
TA1
TAXOL (TN)
TAXOL, 10-EPI,
TXL
TaxAlbin
Taxol
Taxol A
Taxol Konzentrat
Taxol.RTM. (Registered Trademark)
UNII-P88XT4IS4D
UPCMLD-DP108:001
UPCMLD-DP108:002
Vascular Wrap
Xorane
Yewtaxan
abi-007
albumin-bound paclitaxel
cMAP_000068
nab-paclitaxel
nchembio.188-comp1
nchembio.2007.34-comp9
nchembio.215-comp9
nchembio853-comp6
paclitaxel
weekly paclitaxel
4
FesoterodineapprovedPhase 360286930-02-7, 286930-03-86918558
Synonyms:
FESO
 
Fesoterodine
Toviaz
5
TamoxifenapprovedPhase 3, Phase 239010540-29-12733526
Synonyms:
(Z)-1-(p-Dimethylaminoethoxyphenyl)-1,2-diphenyl-1-butene
(Z)-2-(4-(1,2-Diphenyl-1-butenyl)phenoxy)-N,N-dimethylethanamine
(Z)-2-(4-(1,2-diphenylbut-1-enyl)phenoxy)-N,N-dimethylethanamine
(Z)-2-(Para-(1,2-diphenyl-1-butenyl)phenoxy)-N,N-dimethylamine
(Z)-2-(para-(1,2-Diphenyl-1-butenyl)phenoxy)-N,N-dimethylamine (IUPAC)
(Z)-2-[4-(1,2)-DIPHENYL-1-BUTENYL)-PHENOXY]-N,N-DIMETHYLETHANAMINE
(Z)-2-[p-(1,2-Diphenyl-1-butenyl)phenoxy]-N,N-dimethylethylamine
,citrate
1-P-beta-Dimethylaminoethoxyphenyl-trans-1,2-diphenylbut-1-ene
1-Para-beta-dimethylaminoethoxyphenyl-trans-1,2-diphenylbut-1-ene
1-p-.beta.-Dimethylamino-ethoxyphenyl-trans-1,2-diphenylbut-1-ene
1-p-beta-Dimethylaminoethoxyphenyl-trans-1,2-diphenylbut-1-ene
1-para-beta-Dimethylaminoethoxyphenyl-trans-1,2-diphenylbut-1-ene
10540-29-1
1ya4
2-[4-[(Z)-1,2-diphenylbut-1-enyl]phenoxy]-N,N-dimethylethanamine
2-{4-[(1Z)-1,2-diphenylbut-1-en-1-yl]phenoxy}-N,N-dimethylethanamine
54965-24-1 (citrate)
AC1MBZ3R
Apo-Tamox
Apo-tamox
BIDD:ER0008
BIDD:GT0009
BIDD:PXR0003
BPBio1_000278
BRD-K93754473-001-02-9
BRD-K93754473-048-05-3
BSPBio_000252
BSPBio_001150
BSPBio_001982
C07108
C26H29NO
CCRIS 3275
CHEBI:41774
CHEMBL83
CID2733526
Citofen
Crisafeno
D08559
DB00675
Diemon
EINECS 234-118-0
Gen-Tamoxifen
Gen-tamoxifen
HMS1362J11
HMS1792J11
HMS1990J11
HMS2090N08
HSDB 6782
ICI 47699
ICI-46,474
ICI-47699
IDI1_000258
IDI1_002170
Istubol
Kessar
L024126
LS-393
Lopac0_001203
MLS001332535
MLS001332536
MolPort-003-850-384
 
NCGC00024928-01
NCGC00024928-03
NCGC00024928-04
NCGC00024928-05
NCGC00024928-07
NCGC00024928-08
NCGC00024928-09
NCGC00024928-12
NSC727681
Noltam
Nolvadex
Nolvadex-D
Nourytam
Novaldex
Novo-Tamoxifen
Oncomox
PMS-Tamoxifen
Pms-Tamoxifen
Prestwick2_000146
Prestwick3_000146
QTL1_000079
Retaxim
SMR000059172
ST50511785
Spectrum5_001417
Spectrum5_002043
T5648_SIGMA
TAMOXIFEN (TAMOXIFEN CITRATE (54965-24-1))
TRANS FORM OF TAMOXIFEN
Tamizam
Tamofen
Tamone
Tamoplex (TN)
Tamoxasta
Tamoxen
Tamoxifen
Tamoxifen (INN)
Tamoxifen (TN)
Tamoxifen (Z)
Tamoxifen Citrate
Tamoxifen [INN:BAN]
Tamoxifen and its salts
Tamoxifene
Tamoxifene [INN-French]
Tamoxifeno
Tamoxifeno [INN-Spanish]
Tamoxifenum
Tamoxifenum [INN-Latin]
Tamoxifène
Tocris-0999
Tomaxithen
Trans-Tamoxifen
UNII-094ZI81Y45
UPCMLD-DP027
Valodex
Zemide
cMAP_000044
nchembio.140-comp7
nchembio.76-comp1
nchembio732-comp3
tamoxifen
trans-2-[4-(1,2-Diphenyl-1-butenyl)phenoxy]-N,N-dimethylethylamine
trans-Tamoxifen
6
Methylphenidateapproved, investigationalPhase 2, Phase 3375113-45-14158
Synonyms:
.alpha.-Phenyl-2-piperidineacetic acid methyl ester
113-45-1
2-Piperidineacetic acid, .alpha.-phenyl-, methyl ester
2-Piperidineacetic acid, alpha-phenyl-, methyl ester
298-59-9 (hydrochloride)
4311/B Ciba
AC1L1HJM
C 4311
C07196
CHEBI:6887
CHEMBL796
CID4158
Calocain
Centedein
Centedrin
Centedrine
Centredin
Concerta
D-Methylphenidate HCl
D04999
DB00422
DB06701
DEA No. 1724
Daytrana
Daytrana (TN)
EINECS 204-028-6
Focalin
Focalin XR
HSDB 3126
L001307
LS-565
METHYLPHENIDATE (SEE ALSO: METHYLPHENIDATE HYDROCHLORIDE, CAS 298-59-9, NTPNO 10266-R)
MPH
Meridil
Metadate
Metadate CD
Metadate ER
MethyPatch
Methyl (2-phenyl-2-(2-piperidyl)acetate)
Methyl alpha-phenyl-alpha-(2-piperidyl)acetate
Methyl alpha-phenyl-alpha-2-piperidinylacetate
Methyl phenidate
 
Methyl phenidyl acetate
Methyl phenidylacetate
Methylfenidan
Methylin
Methylin ER
Methylofenidan
Methylphen
Methylphenidan
Methylphenidate
Methylphenidate (USAN/INN)
Methylphenidate HCl
Methylphenidate [INN:BAN]
Methylphenidate hydrochloride
Methylphenidatum
Methylphenidatum [INN-Latin]
Methylphenidylacetate hydrochloride
Methypatch
Metilfenidat hydrochloride
Metilfenidato
Metilfenidato [INN-Spanish]
Metilfenidato [Italian]
MolPort-001-779-620
NCI-C56280
PMS-Methylphenidate
Phenidylate
Plimasine
Riphenidate
Ritalin
Ritalin LA
Ritalin SR
Ritalin hydrochloride
Ritalin-SR
Ritaline
Ritcher Works
Ritcher works
Tsentedrin
UNII-207ZZ9QZ49
alpha-Phenyl-2-piperidineacetic acid methyl ester
alpha-Phenyl-alpha-(2-piperidyl)acetic acid methyl ester
d-methylphenidate HCl
methyl 2-phenyl-2-piperidin-2-ylacetate
methyl phenyl(piperidin-2-yl)acetate
methylphenidate
nchembio.2007.55-comp28
7
DopamineapprovedPhase 2, Phase 3383651-61-6, 62-31-7681
Synonyms:
(3H)-Dopamine
.Beta.-(3,4-Dihydroxyphenyl)ethylamine hydrochloride
.alpha.-(3,4-Dihydroxyphenyl)-.beta.-aminoethane
1,2-Benzenediol, 4-(2-aminoethyl)- (9CI)
1,2-Benzenediol, 4-(2-aminoethyl)-, hydrochloride
1,2-Benzenediol, 4-(2-aminoethyl)-, labeled with tritium
153C5321-5FEE-4B0B-8925-F388F0EEEBD1
2-(3,4-Dihydroxyphenyl)ethylamine
2-(3,4-dihydroxyphenyl)ethylamine
2-benzenediol
3,4-Dihydroxyphenethylamine
3,4-Dihydroxyphenethylamine hydrochloride
3,4-Dihydroxyphenylethylamine
3,4-dihydroxyphenethylamine
3-Hydroxtyramine
3-Hydroxytyramine
3-Hydroxytyramine Hydrobromide
3-Hydroxytyramine hydrochloride
4-(2-Aminoethyl)-1,
4-(2-Aminoethyl)-1,2-benzenediol
4-(2-Aminoethyl)-1,2-bezenediol
4-(2-Aminoethyl)-Pyrocatechol
4-(2-Aminoethyl)benzene-1,2-diol
4-(2-Aminoethyl)catechol
4-(2-Aminoethyl)pyrocatechol
4-(2-Aminoethyl)pyrocatechol hydrochloride
4-(2-aminoethyl)-pyrocatechol
50444-17-2
51-61-6
62-31-7 (HYDROCHLORIDE)
AC1L19S5
AC1Q54AX
AC1Q54AY
AKOS003790978
ASL 279
BIDD:ER0506
BPBio1_001123
BSPBio_001932
Biomol-NT_000001
C03758
CHEBI:18243
CHEMBL59
CID681
D07870
DB00988
Deoxyepinephrine
DivK1c_000780
Dopamin
Dopamina
Dopamina [INN-Spanish]
Dopamine
Dopamine (INN)
Dopamine (USAN)(*hydrochloride*)
Dopamine [INN:BAN]
Dopaminum
Dopaminum [INN-Latin]
Dopastat
Dophamine
Dynatra
EINECS 200-110-0
HSDB 3068
Hydroxytyramin
Hydroxytyramine
IDI1_000780
IP 498
Intropin
Intropin [*hydrochloride*]
KBio1_000780
 
KBio2_001492
KBio2_002388
KBio2_002484
KBio2_004060
KBio2_004956
KBio2_005052
KBio2_006628
KBio2_007524
KBio2_007620
KBio3_001152
KBio3_002867
KBio3_002962
KBioGR_001129
KBioGR_002388
KBioGR_002484
KBioSS_001492
KBioSS_002393
KBioSS_002491
KW-3-060
L-DOPAMINE
L000232
LDP
LS-159
Lopac-H-8502
Lopac0_000586
Medopa (TN)
MolPort-001-641-000
NCGC00015519-01
NCGC00015519-08
NCGC00096050-01
NCGC00096050-02
NCGC00096050-03
NCGC00096050-04
NCGC00096050-05
NINDS_000780
NSC 173182
NSC169105
NSC173182
Oprea1_088821
Oxytyramine
Pyrocatechol, 4-(2-aminoethyl)- (8CI)
Pyrocatechol, 4-(2-aminoethyl)-, hydrochloride
Revimine
Revivan
SPBio_001205
SPECTRUM1505155
ST048774
STK301601
Spectrum2_001023
Spectrum3_000406
Spectrum4_000525
Spectrum5_000945
Spectrum_001012
UNII-VTD58H1Z2X
UPCMLD0ENAT5885989:001
a-(3,4-Dihydroxyphenyl)-b-aminoethane
alpha-(3,4-Dihydroxyphenyl)-beta-aminoethane
cMAP_000036
cMAP_000065
dopamine
hydroxytyramine
intropin
m-Hydroxytyramine hydrochloride
nchembio.105-comp9
nchembio.107-comp4
nchembio.284-comp1
nchembio.78-comp16
nchembio.89-comp3
nchembio705-8
nchembio801-comp8
8
Capecitabineapproved, investigationalPhase 3, Phase 21342154361-50-960953
Synonyms:
(1-(5-Deoxy-beta-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinyl)-carbamic acid pentyl ester
154361-50-9
158798-73-3
5'-Deoxy-5-fluoro-N-((pentyloxy)carbonyl)cytidine
5'-deoxy-5-fluoro-N-[(pentyloxy)carbonyl]cytidine
AC1L1U83
AC1Q4KU8
Ambap154361-50-9
C110904
C12650
C15H22FN3O6
CAPE
CAPECITABINE
CHEBI:31348
CHEMBL1773
CID60953
Capecitabin
Capecitabina
Capecitabine (JAN/USAN/INN)
Capecitabine [USAN]
Capecitabinum
Capecitibine
Capiibine
Carbamic acid, (1-(5-deoxy-beta-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinyl)-, pentyl ester
Caxeta
 
D01223
DB01101
FT-0082472
HSDB 7656
LS-59070
MolPort-005-938-254
N(4)-Pentyloxycarbonyl-5'-deoxy-5-fluorocytidine
Pentyl 1-(5-deoxy-beta-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinecarbamate
Pentyl [1-(5-deoxy-beta-D-ribofuranosyl)-5-fluoro-2-oxo-1,2-dihydropyrimidin-4-yl]carbamate
R-340
R340
RG-340
Ro 09-1978
Ro 09-1978/000
Ro-09-1978
Ro-09-1978/000
S1156_Selleck
UNII-6804DJ8Z9U
Xabine
Xeloda
Xeloda (TN)
Xeloda, Captabin, Capecitabine
ZINC03806413
capecitabina
capecitabine
capecitabinum
pentyl N-[1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-methyloxolan-2-yl]-5-fluoro-2-oxopyrimidin-4-yl]carbamate
9
Lamotrigineapproved, investigationalPhase 318584057-84-13878
Synonyms:
3,5-Diamino-6-(2,3-dichlorophenyl)-1,2,4-triazine
3,5-Diamino-6-(2,3-dichlorophenyl)-as-triazine
3,5-diamino-6-(2,3-dichlorophenyl)- as -triazine
6-(2,3-Dichlorophenyl)-1,2,4-triazine-3,5-diyldiamine
6-(2,3-dichlorophenyl)-1,2,4-triazine-3,5-diamine
84057-84-1
AC-10298
AC1L1GWT
BIDD:GT0794
BW 430C
BW-430C
Bio-0056
C047781
CHEBI:138727
CHEBI:6367
CHEMBL741
CID3878
CPD000058464
Crisomet
D00354
DB00555
Desitin Brand of Lamotrigine
EINECS 281-901-8
EU-0100688
EUR-1048
Faes Brand of Lamotrigine
GI 267119X
GW 273293
Glaxo Wellcome Brand of Lamotrigine
GlaxoSmithKline Brand of Lamotrigine
HMS2051C10
HMS2089M08
HMS2093P21
HSDB 7526
Juste Brand of Lamotrigine
L 3791
L3791_SIGMA
LS-155249
 
Labileno
Lamictal
Lamictal (TN)
Lamictal CD
Lamictal Cd
Lamictal ODT
Lamictal XR
Lamictin
Lamiktal
Lamitor
Lamotrigina
Lamotrigina [Spanish]
Lamotrigine
Lamotrigine (JAN/USAN/INN)
Lamotrigine [USAN:INN:BAN]
Lamotriginum
Lamotriginum [Latin]
Lopac-L-3791
Lopac0_000688
MLS000069685
MLS000759486
MLS001077325
MolPort-003-666-744
NCGC00015605-01
NCGC00015605-02
NCGC00015605-06
NCGC00015605-08
NCGC00022936-02
NCGC00022936-04
NCGC00022936-05
NSC746307
SAM001246697
SMP2_000303
SMR000058464
STK628377
Tocris-1611
UNII-U3H27498KS
ZINC00013156
lamotrigine
10
Apomorphineapproved, investigationalPhase 33741372-20-7, 58-00-46005
Synonyms:
(-)-10,11-Dihydroxyaporphine
(6AR)-6-methyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinoline-10,11-diol
(6aR)-5,6,6a,7-Tetrahydro-6-methyl-4H-dibenzo(de,g)chinolin-10,11-diol
(6aR)-6-methyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinoline-10,11-diol
(R)-5,6,6a,7-Tetrahydro-6-methyl-4H-dibenzo[de,g]quinoline-10,11-diol
(R)-5,6,6a,7-tetrahydro-6-methyl-4H-dibenzo[de,g]quinoline-10,11-diol
(R)-6-Methyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinoline-10,11-diol
(−)-10,11-dihydroxyaporphine
314-19-2 (hydrochloride anhydrous)
41372-20-7 (hydrochloride hemihydrate)
4H-Dibenzo(de,g)quinoline-10,11-diol, 5,6,6a,7-tetrahydro-6-methyl-, (R)- (9CI)
4H-Dibenzo(de,g)quinoline-10,11-diol, 5,6,6a,7-tetrahydro-6-methyl-, HCl, (R)-, hemihydrate
58-00-4
6a-beta-Aporphine-10,11-diol
6a-beta-Aporphine-10,11-diol, hydrochloride, hemihydrate
6abeta-Aporphine-10,11-diol
AC1L1LLC
Apokyn
Apomorfin
Apomorphin
Apomorphine (BAN)
Apomorphine HCl hydrate
Apomorphine Hydrochloride Hemihydrate
Apomorphine hydrochloride
Apomorphine hydrochloride hemihydrate
Apomorphinium Chloride Hemihydrate
Apomorphinium chloride hemihydrate
Apormorphine
BPBio1_000092
BPBio1_001179
BRD-K76022557-001-01-3
BSPBio_000082
Biomol-NT_000019
C17H17NO2
 
CE0800000
CHEBI:48538
CID6005
D07460
DB00714
EINECS 200-360-0
HMS2089C10
HSDB 3289
IV Apomorphine
Ixense
L-Apomorphine
LS-21474
NCGC00025349-01
NCGC00025349-02
NIOSH/CE0800000
PDSP1_000780
PDSP2_001488
Prestwick0_000101
Prestwick1_000101
Prestwick2_000101
Prestwick3_000101
R-(-)-Apomorphine
R-(−)-apomorphine
SMP1_000027
SPBio_002021
STOCK1N-03149
Tocris-2073
UNII-N21FAR7B4S
Uprima
Uprima (TN)
VR-040
VR-400
VR004
apomorphine
nchembio.307-comp3
nchembio873-comp6
11
GemcitabineapprovedPhase 3, Phase 1, Phase 2201895058-81-460750
Synonyms:
103882-84-4
122111-03-9
2',2'-DiF-dC
2',2'-Difluoro-2'-deoxycytidine
2',2'-Difluorodeoxycytidine
2'-Deoxy-.beta.-D-2',2'-difluorocytidine
2'-Deoxy-2',2'-difluorocytidine
4-Amino-1-[(2R,4R,5R)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidin-2-one
4-Amino-1-[3,3-difluoro-4-hydroxy-5-(hydroxymethyl) tetrahydrofuran-2-yl]-1H-pyrimidin-2-one
4-amino-1-((2R,4R,5R)-3,3-Difluoro-4-hydroxy-5-(hydroxymethyl)-tetrahydrofuran-2-yl)pyrimidin-2(1H)-one
4-amino-1-((2R,4R,5R)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)-tetrahydrofuran-2-yl)pyrimidin-2(1H)-one
95058-81-4
AB1004842
AC1L1TUQ
C07650
CCRIS 8984
CHEBI:175901
CHEMBL888
CID60750
Cytidine, 2'-deoxy-2',2'-difluoro-2'-Deoxy-.beta.-D-2',2'-difluorocytidine
D02368
DB00441
DDFC
DFDC
DFdC
DFdCyd
Folfugem
GEO
Gamcitabine
GemLip
Gemcel
 
Gemcin
Gemcitabin
Gemcitabina
Gemcitabina [INN-Spanish]
Gemcitabine
Gemcitabine (USAN/INN)
Gemcitabine HCl
Gemcitabine hydrochloride
Gemcitabine stereoisomer
Gemcitabinum
Gemcitabinum [INN-Latin]
Gemtro
Gemzar
Gemzar (hydrochloride)
HMS2089P10
HSDB 7567
Inno-D07001
LS-59139
LY 188011
LY-188011
LY188011
NCGC00168784-01
NChemBio.2007.10-comp25
NSC 613327
NSC613327
TL8005979
UNII-B76N6SBZ8R
ZINC18279854
Zefei
gemcitabine
nchembio.573-comp7
nchembio.90-comp2
12
LevodopaapprovedPhase 340259-92-76047
Synonyms:
(-)-(3,4-Dihydroxyphenyl)alanine
(-)-3-(3,4-Dihydroxyphenyl)-L-alanine
(-)-3-(3,4-dihydroxyphenyl)-L-alanine
(-)-Dopa
(2S)-2-amino-3-(3,4-dihydroxyphenyl)propanoate
(2S)-2-amino-3-(3,4-dihydroxyphenyl)propanoic acid
(−)-3-(3,4-dihydroxyphenyl)-L-alanine
(−)-dopa
.Beta.-(3, 4-Dihydroxyphenyl)alanine
.Beta.-(3,4-Dihydroxyphenyl)-L-alanine
1E83F927-C221-46AA-B90A-81B33C5F3868
2-Amino-3-(3,4-dihydroxyphenyl)propanoic acid
23734-74-9
25525-15-9
3, 4-Dihydroxy-L-phenylalanine
3, 4-Dihydroxyphenylalanine
3,4-DIHYDROXYPHENYLALANINE
3,4-Dihydroxy-L-phenylalanine
3,4-Dihydroxyphenyl-L-alanine
3,4-Dihydroxyphenylalanine
3,4-Dihydroxyphenylalanine (VAN)
3,4-dihydroxy-L-phenylalanine
3,4-dihydroxyphenylalanine
3-(3,4-Dihydroxypheny
3-(3,4-Dihydroxyphenyl)-L-alanine
3-Hydroxy-L-tyrosine
34241-25-3
37830_FLUKA
587-45-1
59-92-7
72572-99-7
72573-00-3
88250-23-1
90638-38-3
AC-11686
AC1L1LOR
AC1Q4U7F
BIDD:GT0158
BPBio1_000059
BSPBio_000053
BSPBio_002354
Bendopa
Bio-0575
Biodopa
Brocadopa
C00355
C9H11NO4
CAS-59-92-7
CCRIS 3766
CHEBI:15765
CHEMBL1009
CID6047
Cerepap
Cidandopa
D 9628
D00059
D0600
D9628
D9628_SIGMA
DAH
DB01235
DOPA
Deadopa
Dihydroxy-L-phenylalanine
Dihydroxyphenylalanine
DivK1c_000452
Dopa
Dopaflex
Dopaidan
Dopal
Dopal-Fher
Dopal-fher
Dopalina
Dopar
Dopar (TN)
Doparkine
Doparl
Dopasol
Dopaston
Dopaston SE
Dopastone
Dopastral
Dopicar
Doprin
EINECS 200-445-2
EU-0100454
Eldopal
Eldopar
Eldopatec
Eurodopa
HMS1568C15
HMS1922J14
HMS2090O08
HMS2093N04
HMS501G14
HSDB 3348
Helfo DOPA
 
Helfo-Dopa
Helfo-dopa
IDI1_000452
IV Levodopa
InChI=1/C9H11NO4/c10-6(9(13)14)3-5-1-2-7(11)8(12)4-5/h1-2,4,6,11-12H,3,10H2,(H,13,14
Insulamina
KBio1_000452
KBio2_000934
KBio2_003502
KBio2_006070
KBioGR_001177
KBioSS_000934
L Dopa
L(-)-Dopa
L-(-)-Dopa
L-(3, 4-Dihydroxyphenyl)-.alpha.-alani
L-(3, 4-Dihydroxyphenyl)alanine
L-(o-Dihydroxyphenyl)alanine
L-.Beta.-(3,4-Dihydroxyphenyl)alanine
L-3,4-Dihydroxyphenylalanine
L-3,4-dihydroxyphenylalanine
L-3-(3,4-Dihydroxyphenyl)-Alanine
L-3-(3,4-Dihydroxyphenyl)alanine
L-3-Hydroxytyrosine
L-4-5-Dihydroxyphenylalanine
L-DOPA
L-DOPA, Parcopa, Atamet, Stalevo, Madopar, Prolopa, Dopar, 3,4-Dihydroxyphenylalanine, Levodopa
L-Dihydroxyphenylalanine
L-Dopa
L-O-Dihydroxyphenylalanine
L-b-(3,4-Dihydroxyphenyl)-a-alanine
L-beta-(3,4-Dihydroxyphenyl)-alpha-alanine
L-beta-(3,4-Dihydroxyphenyl)alanine
L-o-Hydroxytyrosine
LS-255
Laradopa
Larodopa
Ledopa
Levedopa
Levodopa
Levodopa (JP15/USP)
Levodopa (JP15/USP/INN)
Levodopa [USAN:INN:BAN:JAN]
Levodopum
Levodopum [INN-Latin]
Levopa
Lopac-D-9628
Lopac0_000454
MLS000028514
Maipedopa
MolPort-000-856-937
NCGC00015384-01
NCGC00016270-01
NCGC00016270-06
NCGC00093869-04
NINDS_000452
NSC 118381
NSC118381
PDSP1_001541
PDSP2_001525
Parda
Pardopa
Prestwick0_000017
Prestwick1_000017
Prestwick2_000017
Prestwick3_000017
Prestwick_185
Prodopa
Ro 4-6316
S1726_Selleck
SDCCGMLS-0066924.P001
SMR000058312
SPBio_000391
SPBio_001974
SPECTRUM2300205
Sobiodopa
Spectrum2_000496
Spectrum4_000539
Spectrum5_001899
Spectrum_000454
Syndopa
UNII-46627O600J
Veldopa
Weldopa
b-(3,4-Dihydroxyphenyl)-L-alanine
b-(3,4-Dihydroxyphenyl)-a-L-alanine
b-(3,4-Dihydroxyphenyl)alanine
beta-(3,4-Dihydroxyphenyl)-L-alanine
beta-(3,4-Dihydroxyphenyl)-alpha-L-alanine
beta-(3,4-Dihydroxyphenyl)-alpha-alanine
beta-(3,4-Dihydroxyphenyl)alanine
bmse000322
component of Sinemet
l)-L-alanine
nchembio.2007.55-comp26
nchembio.89-comp9
ne
β-(3,4-dihydroxyphenyl)alanine
13
Vinorelbineapproved, investigationalPhase 3, Phase 1, Phase 237471486-22-160780, 44424639
Synonyms:
5'-Noranhydrovinblastine
71486-22-1
AC1L1KVK
AC1L1TWQ
AC1L75Q4
ANX-530
Ambap71486-22-1
BIDD:PXR0186
C45H54N4O8
CHEBI:480999
CHEMBL607994
CID355119
CID5311497
CID5672
CID60780
CID6426842
D08680
DB00361
Eunades
Exelbine
HMS2090E13
HSDB 7665
I06-0084
I06-0085
KW 2307
KW 2307 base
KW-2307
 
LS-97533
MolPort-006-822-661
MolPort-006-823-869
NCGC00165966-02
NVB
Navelbine
Navelbine (TN)
Navelbine Base
Navelbine base
Nor-5'-anhydrovinblastine
SDP-012
UNII-Q6C979R91Y
Vinorelbin
Vinorelbina
Vinorelbina [Spanish]
Vinorelbine
Vinorelbine (INN)
Vinorelbine Bitartrate
Vinorelbine Ditartarate
Vinorelbine Ditartrate
Vinorelbine Tartrate
Vinorelbine [INN:BAN]
Vinorelbine ditartrate
Vinorelbine tartrate
Vinorelbinum
Vinorelbinum [Latin]
methyl (2b,3b,4b,5a,12b,19a)-4-(acetyloxy)-15-[(6R,8S)-4-ethyl-8-(methoxycarbonyl)-1,3,6,7,8,9-hexahydro-2,6-methanoazecino[4,3-b]indol-8-yl]-3-hydroxy-16-methoxy-1-methyl-6,7-didehydroaspidospermidine-3-carboxylate
methyl (2beta,3beta,4beta,5alpha,12beta,19alpha)-4-acetoxy-15-[(6R,8S)-4-ethyl-8-(methoxycarbonyl)-1,3,6,7,8,9-hexahydro-2,6-methanoazecino[4,3-b]indol-8-yl]-3-hydroxy-16-methoxy-1-methyl-6,7-didehydroaspidospermidine-3-carboxylate
vinorelbine
14
CarboplatinapprovedPhase 3205041575-94-410339178, 498142, 38904
Synonyms:
(SP-4-2)-diammine[cyclobutane-1,1-dicarboxylato(2-)-kappa(2)O,O']platinum
/h1-3H2,(H,7,8)(H,9,10)
/q
1,1-Cyclobutanedicarboxylate diammine platinum (II)
1,1-Cyclobutanedicarboxylate diammine platinum(II)
2*-1
2*1H2
41575-94-4
70903-55-8
AC-1457
AC1L8I6U
Ambap41575-94-4
BSPBio_003145
C 2538
C2043
C2538_SIGMA
C6H10N2O4Pt
CBDCA
CCRIS 3404
CHEBI:31355
CHEMBL1351
CHEMBL288376
CID10339178
CID2567
CID38904
CID426756
CID498142
CID5352133
CID6398587
CID6603770
Carbopaltin
Carboplatin
Carboplatin (JAN/USP/INN)
Carboplatin (USAN)
Carboplatin [USAN:INN:BAN:JAN]
Carboplatine
Carboplatine [French]
Carboplatino
Carboplatino [Spanish]
Carboplatinum
Carboplatinum [Latin]
Cbdca
Cyclobutane-1,1-dicarboxylate
D01363
DB00958
Diammine(1,1-cyclobutanedicarboxylato)platinum (II)
Diammine(cyclobutane-1,1-dicarboxylato(2-)-O,O')platinum
Diammine-1,1-cyclobutane dicarboxylate platinum II
DivK1c_000892
EINECS 255-446-0
EU-0100230
Ercar
HMS1921J16
HMS2090M05
HMS2092B22
HMS502M14
HSDB 6957
I14-2390
IDI1_000892
IUPAC: Azane
InChI=1/C6H8O4.2H2N.Pt/c7-4(8)6(5(9)10)2-1-3-6
 
JM 8
JM-8
KBio1_000892
KBio2_002009
KBio2_004577
KBio2_007145
KBio3_002645
KBioGR_000713
KBioSS_002009
LS-117689
Lopac-C-2538
Lopac0_000230
MolPort-003-665-501
MolPort-003-845-609
NCGC00015223-01
NCGC00093695-01
NCGC00094961-01
NCGC00094961-02
NCGC00094961-03
NCGC00162099-01
NCGC00162099-02
NCGC00167800-01
NCGC00178242-01
NINDS_000892
NSC 201345
NSC 241240
NSC-241240
NSC201345
NSC241240
Paraplatin
Paraplatin (TN)
Paraplatin, Carboplatin
Paraplatin-AQ
Platinum(+2) Cation
Platinum(II), (1, 1-cyclobutanedicar
Platinum, diammine(1,1-cyclobutanedicarboxylato(2-)-O,O')-, (SP-4-2)
Platinum, {diammine[1,1-cyclobut
S1215_Selleck
SPBio_000716
SPECTRUM1502106
Spectrum2_000898
Spectrum3_001503
Spectrum4_000337
Spectrum5_001094
Spectrum_001529
UNII-BG3F62OND5
azanide
carboplatin
cis -Diammine[1,1-cyclobutane-dicarboxylato] platinum
cis-(1,1-Cyclobutanedicarboxylato)diammineplatinum(II)
cis-(1,1-Cyclobutanedicarboxylato)diammineplatinum(ii)
cis-Diamine(1,1-cyclobutanedicarboxylato)platinum(II)
cis-Diamine[1,1-cyclobutanedicarboxylato]platinum(II)
cis-Diammine(1,1-cyclobutanedicarboxylato) platinum
cis-Diammine(1,1-cyclobutanedicarboxylato)platinum
cis-Diammine(1,1-cyclobutanedicarboxylato)platinum(II)
cis-Diammine(cyclobutanedicarboxylato)platinum II
cyclobutane-1,1-dicarboxylic acid
diammine[cyclobutane-1,1-dicarboxylato(2-)-k2O1,O1]platinum
nchembio.573-comp10
nchembio773-comp2
nchembio873-comp3
platinum(2+)
15
Dehydroepiandrosteroneapproved, nutraceuticalPhase 2, Phase 39553-43-09860744
Synonyms:
(+)-Dehydroisoandrosterone
(3-beta)-3-Hydroxyandrost-5-en-17-one
(3beta)-3-hydroxy-Androst-5-en-17-one
(3beta,16alpha)-3,16-dihydroxy-androst-5-en-17-one
17-Chetovis
17-Hormoforin
3-beta-Hydroxy-5-androsten-17-one
3-beta-Hydroxyandrost-5-en-17-one
3b-Hydroxy-D5-androsten-17-one
3b-Hydroxyandrost-5-en-17-one
3beta-Hydroxy-D5-androsten-17-one
3beta-Hydroxyandrost-5-en-17-one
3beta-hydroxy-5-androsten-17-one
3beta-hydroxy-Androst-5-en-17-one
3beta-hydroxyandrost-5-en-17-one
3β-hydroxyandrost-5-en-17-one
5,6-Dehydroisoandrosterone
5,6-Didehydroisoandrosterone
5-Androsten-3-beta-ol-17-one
5-Androsten-3b-ol-17-one
5-Androsten-3beta-ol-17-one
5-DHEA
5-Dehydro-Epiandrosterone
 
5-Dehydroepiandrosterone
5-dehydroepiandrosterone
Andrestenol
Androst-5-ene-3b-ol-17-one
Androst-5-ene-3beta-ol-17-one
Androsten-3beta-ol-17-one
Androstenolone
Astenile
D5-Androsten-3b-ol-17-one
D5-Androsten-3beta-ol-17-one
DHEA
Deandros
Dehydro-epi-androsterone
Dehydroandrosterone
Dehydroepiandrosterone
Dehydroisoandrosterone
Diandron
Diandrone
Hydroxyandrostenone
Prasterona
Prasterone
Prasteronum
Prestara
Psicosterone
trans-Dehydroandrosterone
16
Docetaxelapproved, investigational, Approved May 1996Phase 3, Phase 2, Phase 11967114977-28-5148124, 9877265
Synonyms:
(2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,6,11-trihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl (aR,bS)-b-[[(1,1-dimethylethoxy)carbonyl]amino]-a-hydroxybenzenepropanoate
(2alpha,5beta,7beta,10beta,13alpha)-4-(acetyloxy)-13-({(2R,3S)-3-[(tert-butoxycarbonyl)amino]-2-hydroxy-3-phenylpropanoyl}oxy)-1,7,10-trihydroxy-9-oxo-5,20-epoxytax-11-en-2-yl benzoate
01885_FLUKA
114977-28-5
4-(Acetyloxy)-13alpha-({(2R,3S)-3-[(tert-butoxycarbonyl)amino]-2-hydroxy-3-phenylpropanoyl}oxy)-1,7beta,10beta-trihydroxy-9-oxo-5beta,20-epoxytax-11-en-2alpha-yl benzoate
4-(acetyloxy)-13alpha-({(2R,3S)-3-[(tert-butoxycarbonyl)amino]-2-hydroxy-3-phenylpropanoyl}oxy)-1,7beta,10beta-trihydroxy-9-oxo-5beta,20-epoxytax-11-en-2alpha-yl benzoate
AC-383
AC1L3WHJ
ANX-514
BIND-014
C11231
CHEBI:4672
CHEMBL92
CID148124
D07866
DB01248
Docetaxel
Docetaxel (INN)
Docetaxel anhydrous
Docetaxel, Trihydrate
EmDOC
 
HMS2089K08
InChI=1/C43H53NO14/c1-22-26(55-37(51)32(48)30(24-15-11-9-12-16-24)44-38(52)58-39(3,4)5)20-43(53)35(56-36(50)25-17-13-10-14-18-25)33-41(8,34(49)31(47)29(22)40(43,6)7)27(46)19-28-42(33,21-54-28)57-23(2)45/h9-18,26-28,30-33,35,46-48,53H,19-21H2,1-8H3,(H,44,5
MolPort-003-847-005
N-Debenzoyl-N-(tert-butoxycarbonyl)-10-deacetylpaclitaxel
N-Debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol
N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetylpaclitaxel
N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol
N-debenzoyl-N-Boc-10-deacetyl taxol
NSC-628503
PSMA-targeted docetaxel nanoparticle
RP-56976
SDP-014
TXL
Taxotere
Taxotere (TN)
Taxotere(R)
XRP-6976L
docetaxel
docetaxel 114977-28-5
nchembio.188-comp8
nchembio.2007.34-comp7
nchembio.573-comp11
nchembio853-comp8
17
Lapatinibapproved, investigational, Approved March 2007Phase 3, Phase 1, Phase 2301231277-92-2, 388082-78-8208908, 9941095
Synonyms:
1xkk
231277-92-2
388082-78-8
4-[[3-Chloro-4-(3-fluorobenzyloxy)phenyl]amino]-6-[5-[[(2-methanesulfonylethyl)amino]methyl]furan-2-yl]quinazoline
AB1004631
AC-1314
AC1L4LL4
AKOS005145766
CHEBI:49603
CHEMBL1201179
CHEMBL554
CID11557040
CID208908
D04024
D08108
DB01259
DB02584
EN002712
FMM
GSK 572016
GSK572016
GW 572016
GW 572016X
GW-2016
GW-572016
GW-572016F
GW2016
GW572016
HMS2089H10
I01-1247
 
Kinome_3684
Kinome_3685
LAPATINIB DITOSYLATE MONOHYDRATE
LS-187029
LS-187771
Lapatinib
Lapatinib (INN)
Lapatinib Ditosylate
Lapatinib [INN]
Lapatinib ditosylate
Lapatinib ditosylate (USAN)
Lapatinib tosilate hydrate
Lapatinib tosilate hydrate (JAN)
Lapatinib, Tykerb, GW572016
N-(3-Chloro-4-((3-fluorophenyl)methoxy)phenyl)-6-(5-((2-methylsulfonylethylamino)methyl)-2-furyl)quinazolin-4-amine
N-(3-Chloro-4-{[(3-fluorophenyl)methyl]oxy}phenyl)-6-[5-({[2-(methylsulfonyl)ethyl]amino}methyl)-2-furanyl]-4-quinazolinamine
N-(3-chloro-4-((3-Fluorophenyl)methoxy)phenyl)-6-(5-(((2-(methylsulfonyl)ethyl)amino)methyl)-2-furanyl)-4-quinazolinamine
N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-[5-[(2-methylsulfonylethylamino)methyl]furan-2-yl]quinazolin-4-amine
N-{3-CHLORO-4-[(3-FLUOROBENZYL)OXY]PHENYL}-6-[5-({[2-(METHYLSULFONYL)ETHYL]AMINO}METHYL)-2-FURYL]-4-QUINAZOLINAMINE
N-{3-chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2-(methylsulfonyl)ethyl]amino}methyl)-2-furyl]-4-quinazolinamine
NCGC00167507-01
NSC745750
TL80090051
Tycerb
Tykerb
Tykerb (TN)
Tyverb
UNII-0VUA21238F
lapatinib
lapatinib ditosylate
nchembio866-comp20
18Ado-trastuzumab emtansinePhase 3, Phase 2, Phase 168
19HormonesPhase 3, Phase 1, Phase 214415
20MitogensPhase 3, Phase 2, Phase 11617
21Aromatase InhibitorsPhase 3, Phase 2826
22Prolactin Release-Inhibiting FactorsPhase 3, Phase 276
23Anti-Infective AgentsPhase 3, Phase 1, Phase 222062
24Gastrointestinal AgentsPhase 3, Phase 18402
25Peripheral Nervous System AgentsPhase 3, Phase 123689
26AnticonvulsantsPhase 32695
27Autonomic AgentsPhase 3, Phase 110150
28Antiviral AgentsPhase 3, Phase 1, Phase 29967
29Muscarinic AntagonistsPhase 31166
30AcyclovirPhase 3183
31Protein Kinase InhibitorsPhase 3, Phase 1, Phase 23689
32Cholinergic AntagonistsPhase 31706
33Cholinergic AgentsPhase 33992
34Neurotransmitter AgentsPhase 3, Phase 218340
35Sodium Channel BlockersPhase 3, Phase 21593
36Central Nervous System StimulantsPhase 2, Phase 32211
37Dopamine AgentsPhase 2, Phase 33836
38Excitatory Amino AcidsPhase 3, Phase 21362
39Excitatory Amino Acid AntagonistsPhase 3, Phase 21347
40calcium channel blockersPhase 31985
41Calcium, DietaryPhase 35713
42Antimetabolites, AntineoplasticPhase 3, Phase 2, Phase 17361
43Dopamine Uptake InhibitorsPhase 2, Phase 31331
44Diuretics, Potassium SparingPhase 3, Phase 21917
45Antineoplastic Agents, PhytogenicPhase 3, Phase 2, Phase 15602
46taxanePhase 3, Phase 2, Phase 1354
47Neurotransmitter Uptake InhibitorsPhase 2, Phase 33521
48AntimetabolitesPhase 3, Phase 2, Phase 112054
49Antimitotic AgentsPhase 3, Phase 2, Phase 15657
50MaytansinePhase 3, Phase 2, Phase 175

Interventional clinical trials:

(show top 50)    (show all 129)
idNameStatusNCT IDPhase
1RAMYD Study - Evaluation of Arrhythmic Risk in Myotonic DystrophyUnknown statusNCT00127582Phase 3
2Lamotrigine as Treatment of MyotoniaCompletedNCT01939561Phase 3
3Methylphenidate in Myotonic Dystrophy Type 1CompletedNCT01421992Phase 2, Phase 3
4Efficacy and Safety of DHEA for Myotonic DystrophyCompletedNCT00167609Phase 2, Phase 3
5A Study of Trastuzumab Emtansine (T-DM1) Plus Pertuzumab/Pertuzumab Placebo Versus Trastuzumab [Herceptin] Plus a Taxane in Patients With Metastatic Breast Cancer (MARIANNE)CompletedNCT01120184Phase 3
6A Study of Trastuzumab Emtansine Versus Capecitabine + Lapatinib in Participants With HER2-positive Locally Advanced or Metastatic Breast CancerCompletedNCT00829166Phase 3
7A Study of Trastuzumab Emtansine in Comparison With Treatment of Physician's Choice in Participants With HER2-positive Breast Cancer Who Have Received at Least Two Prior Regimens of HER2-directed TherapyCompletedNCT01419197Phase 3
8Long-Term Open-Label Extension Trial for Subjects Completing the Phase 3 Trial of Fesoterodine (SP583) for the Treatment of Overactive Bladder SyndromeCompletedNCT00220402Phase 3
9A Multicenter Trial to Investigate Fesoterodine Sustained Release in Overactive Bladder SyndromeCompletedNCT00220363Phase 3
10Safety and Efficacy of a Violet Visible Light Blocking Intraocular Lens (IOL)CompletedNCT00747227Phase 3
11Phase 3 Clinical Study for the Treatment of Cold SoreCompletedNCT00769314Phase 3
12PD P 506 A-PDT Versus Placebo-PDT and Cryosurgery for the Treatment of AKCompletedNCT00308867Phase 3
13A Study of Trastuzumab Emtansine in Participants With Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer Who Have Received Prior Anti-HER2 And Chemotherapy-based TreatmentRecruitingNCT01702571Phase 3
14A Phase III Trial of Pertuzumab Retreatment in Previously Pertuzumab Treated Her2-Positive Advanced Breast CancerRecruitingNCT02514681Phase 3
15An Open-Label Phase 3 Study to Examine the Long-Term Safety, Tolerability and Efficacy of APL-130277 for the Acute Treatment of "OFF" Episodes in Patients With Parkinson's DiseaseRecruitingNCT02542696Phase 3
16Efficacy and Tolerance of Early Launching of Nocturnal Non InvasiveActive, not recruitingNCT01225614Phase 3
17A Study Evaluating Trastuzumab Emtansine Plus Pertuzumab Compared With Chemotherapy Plus Trastuzumab and Pertuzumab for Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast CancerActive, not recruitingNCT02131064Phase 3
18Efficacy and Safety of Trastuzumab Emtansine in Chinese Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Locally Advanced or Metastatic Breast CancerNot yet recruitingNCT03084939Phase 3
19A Study of Trastuzumab Emtansine Versus Taxane in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Gastric CancerTerminatedNCT01641939Phase 2, Phase 3
20Safety and Efficacy Study of Recombinant Human Insulin-Like Growth Factor-I/Recombinant Human Insulin-Like Growth Factor Binding Protein-3 (rhIGF-I/rhIGFBP-3) In Myotonic Dystrophy Type 1Unknown statusNCT00577577Phase 2
21A Safety andTolerability Study of Multiple Doses of ISIS-DMPKRx in Adults With Myotonic Dystrophy Type 1CompletedNCT02312011Phase 1, Phase 2
22Clinical Efficacy Trial of Mexiletine for Myotonic Dystrophy Type 1CompletedNCT01406873Phase 2
23Effects of SomatoKine (Iplex)Recombinant Human Insulin-like Growth Factor-1/Recombinant Human Insulin-like Growth Factor-binding Protein-3 (rhIGF-I/rhIGFBP-3) in Myotonic Dystrophy Type 1 (DM1)CompletedNCT00233519Phase 1, Phase 2
24A Study of Trastuzumab Emtansine (T-DM1) in Combination With Docetaxel, and Potentially Pertuzumab, in Participants With Advanced Breast CancerCompletedNCT00934856Phase 1, Phase 2
25Corrected QT Interval Effects of Trastuzumab Emtansine (T-DM1) in Patients With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Locally Advanced or Metastatic Breast Cancer and the Safety and Tolerability of Combined T-DM1 and Pertuzumab in PatieCompletedNCT00943670Phase 2
26A Study of Trastuzumab-Mcc-DM1 Administered Intravenously to Patients With HER2-Positive Metastatic Breast CancerCompletedNCT00679211Phase 2
27A Study of Trastuzumab Emtansine (Trastuzumab-MCC-DM1) Administered Intravenously to Patients With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast CancerCompletedNCT00509769Phase 2
28A Study of Trastuzumab Emtansine (Trastuzumab-MCC-DM1, T-DM1) in Combination With Pertuzumab Administered to Patients With Human Epidermal Growth Factor Receptor-2 (HER2)-Positive Locally Advanced or Metastatic Breast Cancer Who Have Previously Received TCompletedNCT00875979Phase 1, Phase 2
29A Study of the Efficacy and Safety of Trastuzumab Emtansine (Trastuzumab-MCC-DM1) vs. Trastuzumab (Herceptin®) and Docetaxel (Taxotere®) in Patients With Metastatic HER2-positive Breast Cancer Who Have Not Received Prior Chemotherapy for Metastatic DiseasCompletedNCT00679341Phase 2
30A Study of Trastuzumab Emtansine (T-DM1) Sequentially With Anthracycline-based Chemotherapy, as Adjuvant or Neoadjuvant Therapy for Patients With Early Stage Herceptin (HER)2-positive Breast CancerCompletedNCT01196052Phase 2
31MLN2704 in Subjects With Metastatic Androgen-Independent Prostate CancerCompletedNCT00070837Phase 1, Phase 2
32A Study of Trastuzumab Emtansine, Paclitaxel, and Pertuzumab in Patients With HER2-Positive, Locally Advanced or Metastatic Breast CancerCompletedNCT00951665Phase 1, Phase 2
33Study of Ranolazine in Myotonia Congenita, Paramyotonia Congenita and Myotonic Dystrophy Type 1RecruitingNCT02251457Phase 2
34Study of Tideglusib in Adolescent and Adult Patients With Myotonic DystrophyRecruitingNCT02858908Phase 2
35A Dose-Escalation Study Evaluating the Combination of Trastuzumab Emtansine (T-DM1) With Neratinib in Women With Metastatic HER2-Positive Breast CancerRecruitingNCT02236000Phase 1, Phase 2
36T-DM1 vs Paclitaxel/Trastuzumab for Breast (ATEMPT Trial)RecruitingNCT01853748Phase 2
37T-DM1+Pertuzumab in Pre-OP Early-Stage HER2+ BRCARecruitingNCT02326974Phase 2
38HER2 Imaging Study to Identify HER2 Positive Metastatic Breast Cancer Patient Unlikely to Benefit From T-DM1RecruitingNCT01565200Phase 2
39An Open-Label, Phase Ib/II Clinical Trial Of Cdk 4/6 Inhibitor, Ribociclib (Lee011), In Combination With Trastuzumab Or T-Dm1 For Advanced/Metastatic Her2-Positive Breast Cancer.RecruitingNCT02657343Phase 1, Phase 2
40Vinorelbine With Trastuzumab Emtansine in Pre-Treated HER2-Positive Metastatic Breast CancerRecruitingNCT02658084Phase 1, Phase 2
41Trastuzumab Emtansine in Treating Older Patients With Human Epidermal Growth Factor Receptor 2-Positive Stage I-III Breast CancerRecruitingNCT02414646Phase 2
42Deciphering Antitumour Response and Resistance With INtratumour HeterogeneityRecruitingNCT02314481Phase 2
43A Study to Evaluate the Efficacy and Safety of Trastuzumab Emtansine in Combination With Atezolizumab or Atezolizumab-Placebo in Participants With Human Epidermal Growth Factor-2 (HER2) Positive Locally Advanced or Metastatic Breast Cancer Who Have ReceivRecruitingNCT02924883Phase 2
44TDM1 With Abraxane and Lapatinib for Metastatic HER2 Positive Breast CancerRecruitingNCT02073916Phase 1, Phase 2
45Transplantation of Autologous Stem Cells for the Treatment of Type 1 Diabetes MellitusRecruitingNCT02644759Phase 1, Phase 2
46I-SPY 2 TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast CancerRecruitingNCT01042379Phase 2
47A Safety Extension Study of Trastuzumab Emtansine in Participants Previously Treated With Trastuzumab Emtansine Alone or in Combination With Other Anti-Cancer Therapy in One of the Parent StudiesRecruitingNCT00781612Phase 2
48NEOADjuvant Aromatase Inhibitor and Pertuzumab/Trastuzumab for Women With Breast CancerRecruitingNCT02689921Phase 2
49NCI-MATCH: Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple MyelomaRecruitingNCT02465060Phase 2
50A Prospective, Randomized Multicenter, Open-label Comparison of Preoperative Trastuzumab Emtansine (T-DM1) With or Without Standard Endocrine Therapy vs. Trastuzumab With Standard Endocrine Therapy Given for Twelve Weeks in Patients With Operable HER2+/HRActive, not recruitingNCT01745965Phase 2

Search NIH Clinical Center for Myotonic Dystrophy 1


Cochrane evidence based reviews: myotonic dystrophy

Genetic Tests for Myotonic Dystrophy 1

About this section

Genetic tests related to Myotonic Dystrophy 1:

id Genetic test Affiliating Genes
1 Steinert Myotonic Dystrophy Syndrome27
2 Myotonic Dystrophy Type 124 DMPK

Anatomical Context for Myotonic Dystrophy 1

About this section

MalaCards organs/tissues related to Myotonic Dystrophy 1:

36
Skeletal muscle, Heart, Eye, Smooth muscle, Brain

Publications for Myotonic Dystrophy 1

About this section

Articles related to Myotonic Dystrophy 1:

(show all 21)
idTitleAuthorsYear
1
Renal dysfunction can be a common complication in patients with myotonic dystrophy 1. (27538647)
2016
2
Modeling Myotonic Dystrophy 1 in C2C12 Myoblast Cells. (27501221)
2016
3
Computational Investigation of RNA CUG Repeats Responsible for Myotonic Dystrophy 1. (26500461)
2015
4
Recurrent takotsubo syndrome in a patient with myotonic dystrophy 1. (25101654)
2014
5
Noncompaction predisposing for recurrent Takotsubo syndrome in myotonic dystrophy 1. (23890854)
2013
6
Beneficial effect of digitoxin for heart failure from noncompaction in myotonic dystrophy 1. (22475848)
2012
7
A myotonic dystrophy 1 patient complicated with placental adherence after miscarriage of one dichorionic diamniotic twin following her tenth in vitro fertilization and embryo transfer. (23011730)
2012
8
The brain in myotonic dystrophy 1 and 2: evidence for a predominant white matter disease. (22131273)
2011
9
Implantable loop recorders in myotonic dystrophy 1. (21880381)
2011
10
Gastroparesis in myotonic dystrophy 1. (21125412)
2011
11
Expansion of CUG RNA repeats causes stress and inhibition of translation in myotonic dystrophy 1 (DM1) cells. (20479119)
2010
12
Pneumosinus dilatans and hypercalcification of the falx and ligamentum petroclinoideum in myotonic dystrophy 1. (20220451)
2010
13
Comparative analysis of brain structure, metabolism, and cognition in myotonic dystrophy 1 and 2. (20220122)
2010
14
New analysis method of myotonic dystrophy 1 based on quantitative fluorescent polymerase chain reaction. (19715468)
2009
15
Myotonic dystrophy 1 in the nervous system: from the clinic to molecular mechanisms. (17549748)
2008
16
Myotonic dystrophy protein kinase (DMPK) and its role in the pathogenesis of myotonic dystrophy 1. (18583094)
2008
17
Increased steady-state levels of CUGBP1 in myotonic dystrophy 1 are due to PKC-mediated hyperphosphorylation. (17936705)
2007
18
Asymptomatic, progressive electrocardiographic abnormalities over twelve years in myotonic dystrophy 1. (17982974)
2007
19
Altered expression of CUG binding protein 1 mRNA in myotonic dystrophy 1: possible RNA-RNA interaction. (15099703)
2004
20
Decreased DMPK transcript levels in myotonic dystrophy 1 type IIA muscle fibers. (11527424)
2001
21
Independent regulation of the myotonic dystrophy 1 locus genes postnatally and during adult skeletal muscle regeneration. (10748037)
2000

Variations for Myotonic Dystrophy 1

About this section

Clinvar genetic disease variations for Myotonic Dystrophy 1:

5 (show all 141)
id Gene Variation Type Significance SNP ID Assembly Location
1DMPKNM_ 004409.4(DMPK): c.*224_ *226[102]NT expansionPathogenicrs786200945GRCh38Chr 19, 45770262: 45770264
2DMPKNM_ 004409.4(DMPK): c.*224_ *226[103]NT expansionPathogenicrs786200945GRCh38Chr 19, 45770262: 45770264
3DMPKNM_ 004409.4(DMPK): c.*224_ *226[107]NT expansionPathogenicrs786200945GRCh38Chr 19, 45770262: 45770264
4DMPKNM_ 004409.4(DMPK): c.*224_ *226[1080]NT expansionPathogenicrs786200945GRCh38Chr 19, 45770262: 45770264
5DMPKNM_ 004409.4(DMPK): c.*224_ *226[1140]NT expansionPathogenicrs786200945GRCh38Chr 19, 45770262: 45770264
6DMPKNM_ 004409.4(DMPK): c.*224_ *226[1142]NT expansionPathogenicrs786200945GRCh38Chr 19, 45770262: 45770264
7DMPKNM_ 004409.4(DMPK): c.*224_ *226[1189]NT expansionPathogenicrs786200945GRCh38Chr 19, 45770262: 45770264
8DMPKNM_ 004409.4(DMPK): c.*224_ *226[122]NT expansionPathogenicrs786200945GRCh38Chr 19, 45770262: 45770264
9DMPKNM_ 004409.4(DMPK): c.*224_ *226[123]NT expansionPathogenicrs786200945GRCh38Chr 19, 45770262: 45770264
10DMPKNM_ 004409.4(DMPK): c.*224_ *226[1236]NT expansionPathogenicrs786200945GRCh37Chr 19, 46273520: 46273522
11DMPKNM_ 004409.4(DMPK): c.*224_ *226[124]NT expansionPathogenicrs786200945GRCh38Chr 19, 45770262: 45770264
12DMPKNM_ 004409.4(DMPK): c.*224_ *226[127]NT expansionPathogenicrs786200945GRCh38Chr 19, 45770262: 45770264
13DMPKNM_ 004409.4(DMPK): c.*224_ *226[131]NT expansionPathogenicrs786200945GRCh38Chr 19, 45770262: 45770264
14DMPKNM_ 004409.4(DMPK): c.*224_ *226[132]NT expansionPathogenicrs786200945GRCh37Chr 19, 46273520: 46273522
15DMPKNM_ 004409.4(DMPK): c.*224_ *226[134]NT expansionPathogenicrs786200945GRCh37Chr 19, 46273520: 46273522
16DMPKNM_ 004409.4(DMPK): c.*224_ *226[135]NT expansionPathogenicrs786200945GRCh38Chr 19, 45770262: 45770264
17DMPKNM_ 004409.4(DMPK): c.*224_ *226[142]NT expansionPathogenicrs786200945GRCh38Chr 19, 45770262: 45770264
18DMPKNM_ 004409.4(DMPK): c.*224_ *226[146]NT expansionPathogenicrs786200945GRCh37Chr 19, 46273520: 46273522
19DMPKNM_ 004409.4(DMPK): c.*224_ *226[1502]NT expansionPathogenicrs786200945GRCh38Chr 19, 45770262: 45770264
20DMPKNM_ 004409.4(DMPK): c.*224_ *226[158]NT expansionPathogenicrs786200945GRCh38Chr 19, 45770262: 45770264
21DMPKNM_ 004409.4(DMPK): c.*224_ *226[160]NT expansionPathogenicrs786200945GRCh37Chr 19, 46273520: 46273522
22DMPKNM_ 004409.4(DMPK): c.*224_ *226[168]NT expansionPathogenicrs786200945GRCh38Chr 19, 45770262: 45770264
23DMPKNM_ 004409.4(DMPK): c.*224_ *226[1681]NT expansionPathogenicrs786200945GRCh38Chr 19, 45770262: 45770264
24DMPKNM_ 004409.4(DMPK): c.*224_ *226[169]NT expansionPathogenicrs786200945GRCh37Chr 19, 46273520: 46273522
25DMPKNM_ 004409.4(DMPK): c.*224_ *226[175]NT expansionPathogenicrs786200945GRCh38Chr 19, 45770262: 45770264
26DMPKNM_ 004409.4(DMPK): c.*224_ *226[181]NT expansionPathogenicrs786200945GRCh38Chr 19, 45770262: 45770264
27DMPKNM_ 004409.4(DMPK): c.*224_ *226[182]NT expansionPathogenicrs786200945GRCh38Chr 19, 45770262: 45770264
28DMPKNM_ 004409.4(DMPK): c.*224_ *226[194]NT expansionPathogenicrs786200945GRCh37Chr 19, 46273520: 46273522
29DMPKNM_ 004409.4(DMPK): c.*224_ *226[195]NT expansionPathogenicrs786200945GRCh38Chr 19, 45770262: 45770264
30DMPKNM_ 004409.4(DMPK): c.*224_ *226[197]NT expansionPathogenicrs786200945GRCh37Chr 19, 46273520: 46273522
31DMPKNM_ 004409.4(DMPK): c.*224_ *226[214]NT expansionPathogenicrs786200945GRCh38Chr 19, 45770262: 45770264
32DMPKNM_ 004409.4(DMPK): c.*224_ *226[216]NT expansionPathogenicrs786200945GRCh38Chr 19, 45770262: 45770264
33DMPKNM_ 004409.4(DMPK): c.*224_ *226[225]NT expansionPathogenicrs786200945GRCh37Chr 19, 46273520: 46273522
34DMPKNM_ 004409.4(DMPK): c.*224_ *226[229]NT expansionPathogenicrs786200945GRCh38Chr 19, 45770262: 45770264
35DMPKNM_ 004409.4(DMPK): c.*224_ *226[232]NT expansionPathogenicrs786200945GRCh37Chr 19, 46273520: 46273522
36DMPKNM_ 004409.4(DMPK): c.*224_ *226[235]NT expansionPathogenicrs786200945GRCh38Chr 19, 45770262: 45770264
37DMPKNM_ 004409.4(DMPK): c.*224_ *226[236]NT expansionPathogenicrs786200945GRCh38Chr 19, 45770262: 45770264
38DMPKNM_ 004409.4(DMPK): c.*224_ *226[238]NT expansionPathogenicrs786200945GRCh38Chr 19, 45770262: 45770264
39DMPKNM_ 004409.4(DMPK): c.*224_ *226[241]NT expansionPathogenicrs786200945GRCh38Chr 19, 45770262: 45770264
40DMPKNM_ 004409.4(DMPK): c.*224_ *226[255]NT expansionPathogenicrs786200945GRCh37Chr 19, 46273520: 46273522
41DMPKNM_ 004409.4(DMPK): c.*224_ *226[256]NT expansionPathogenicrs786200945GRCh37Chr 19, 46273520: 46273522
42DMPKNM_ 004409.4(DMPK): c.*224_ *226[260]NT expansionPathogenicrs786200945GRCh38Chr 19, 45770262: 45770264
43DMPKNM_ 004409.4(DMPK): c.*224_ *226[261]NT expansionPathogenicrs786200945GRCh38Chr 19, 45770262: 45770264
44DMPKNM_ 004409.4(DMPK): c.*224_ *226[264]NT expansionPathogenicrs786200945GRCh38Chr 19, 45770262: 45770264
45DMPKNM_ 004409.4(DMPK): c.*224_ *226[265]NT expansionPathogenicrs786200945GRCh38Chr 19, 45770262: 45770264
46DMPKNM_ 004409.4(DMPK): c.*224_ *226[271]NT expansionPathogenicrs786200945GRCh38Chr 19, 45770262: 45770264
47DMPKNM_ 004409.4(DMPK): c.*224_ *226[281]NT expansionPathogenicrs786200945GRCh38Chr 19, 45770262: 45770264
48DMPKNM_ 004409.4(DMPK): c.*224_ *226[303]NT expansionPathogenicrs786200945GRCh38Chr 19, 45770262: 45770264
49DMPKNM_ 004409.4(DMPK): c.*224_ *226[307]NT expansionPathogenicrs786200945GRCh38Chr 19, 45770262: 45770264
50DMPKNM_ 004409.4(DMPK): c.*224_ *226[313]NT expansionPathogenicrs786200945GRCh38Chr 19, 45770262: 45770264
51DMPKNM_ 004409.4(DMPK): c.*224_ *226[318]NT expansionPathogenicrs786200945GRCh38Chr 19, 45770262: 45770264
52DMPKNM_ 004409.4(DMPK): c.*224_ *226[327]NT expansionPathogenicrs786200945GRCh37Chr 19, 46273520: 46273522
53DMPKNM_ 004409.4(DMPK): c.*224_ *226[333]NT expansionPathogenicrs786200945GRCh38Chr 19, 45770262: 45770264
54DMPKNM_ 004409.4(DMPK): c.*224_ *226[339]NT expansionPathogenicrs786200945GRCh37Chr 19, 46273520: 46273522
55DMPKNM_ 004409.4(DMPK): c.*224_ *226[345]NT expansionPathogenicrs786200945GRCh38Chr 19, 45770262: 45770264
56DMPKNM_ 004409.4(DMPK): c.*224_ *226[347]NT expansionPathogenicrs786200945GRCh37Chr 19, 46273520: 46273522
57DMPKNM_ 004409.4(DMPK): c.*224_ *226[351]NT expansionPathogenicrs786200945GRCh38Chr 19, 45770262: 45770264
58DMPKNM_ 004409.4(DMPK): c.*224_ *226[352]NT expansionPathogenicrs786200945GRCh37Chr 19, 46273520: 46273522
59DMPKNM_ 004409.4(DMPK): c.*224_ *226[353]NT expansionPathogenicrs786200945GRCh38Chr 19, 45770262: 45770264
60DMPKNM_ 004409.4(DMPK): c.*224_ *226[354]NT expansionPathogenicrs786200945GRCh37Chr 19, 46273520: 46273522
61DMPKNM_ 004409.4(DMPK): c.*224_ *226[364]NT expansionPathogenicrs786200945GRCh38Chr 19, 45770262: 45770264
62DMPKNM_ 004409.4(DMPK): c.*224_ *226[371]NT expansionPathogenicrs786200945GRCh38Chr 19, 45770262: 45770264
63DMPKNM_ 004409.4(DMPK): c.*224_ *226[372]NT expansionPathogenicrs786200945GRCh38Chr 19, 45770262: 45770264
64DMPKNM_ 004409.4(DMPK): c.*224_ *226[373]NT expansionPathogenicrs786200945GRCh37Chr 19, 46273520: 46273522
65DMPKNM_ 004409.4(DMPK): c.*224_ *226[375]NT expansionPathogenicrs786200945GRCh38Chr 19, 45770262: 45770264
66DMPKNM_ 004409.4(DMPK): c.*224_ *226[376]NT expansionPathogenicrs786200945GRCh37Chr 19, 46273520: 46273522
67DMPKNM_ 004409.4(DMPK): c.*224_ *226[377]NT expansionPathogenicrs786200945GRCh38Chr 19, 45770262: 45770264
68DMPKNM_ 004409.4(DMPK): c.*224_ *226[391]NT expansionPathogenicrs786200945GRCh37Chr 19, 46273520: 46273522
69DMPKNM_ 004409.4(DMPK): c.*224_ *226[395]NT expansionPathogenicrs786200945GRCh37Chr 19, 46273520: 46273522
70DMPKNM_ 004409.4(DMPK): c.*224_ *226[397]NT expansionPathogenicrs786200945GRCh38Chr 19, 45770262: 45770264
71DMPKNM_ 004409.4(DMPK): c.*224_ *226[398]NT expansionPathogenicrs786200945GRCh37Chr 19, 46273520: 46273522
72DMPKNM_ 004409.4(DMPK): c.*224_ *226[407]NT expansionPathogenicrs786200945GRCh37Chr 19, 46273520: 46273522
73DMPKNM_ 004409.4(DMPK): c.*224_ *226[421]NT expansionPathogenicrs786200945GRCh37Chr 19, 46273520: 46273522
74DMPKNM_ 004409.4(DMPK): c.*224_ *226[435]NT expansionPathogenicrs786200945GRCh38Chr 19, 45770262: 45770264
75DMPKNM_ 004409.4(DMPK): c.*224_ *226[436]NT expansionPathogenicrs786200945GRCh38Chr 19, 45770262: 45770264
76DMPKNM_ 004409.4(DMPK): c.*224_ *226[437]NT expansionPathogenicrs786200945GRCh37Chr 19, 46273520: 46273522
77DMPKNM_ 004409.4(DMPK): c.*224_ *226[440]NT expansionPathogenicrs786200945GRCh38Chr 19, 45770262: 45770264
78DMPKNM_ 004409.4(DMPK): c.*224_ *226[448]NT expansionPathogenicrs786200945GRCh38Chr 19, 45770262: 45770264
79DMPKNM_ 004409.4(DMPK): c.*224_ *226[449]NT expansionPathogenicrs786200945GRCh37Chr 19, 46273520: 46273522
80DMPKNM_ 004409.4(DMPK): c.*224_ *226[455]NT expansionPathogenicrs786200945GRCh38Chr 19, 45770262: 45770264
81DMPKNM_ 004409.4(DMPK): c.*224_ *226[46]NT expansionPathogenicrs786200945GRCh37Chr 19, 46273520: 46273522
82DMPKNM_ 004409.4(DMPK): c.*224_ *226[461]NT expansionPathogenicrs786200945GRCh38Chr 19, 45770262: 45770264
83DMPKNM_ 004409.4(DMPK): c.*224_ *226[462]NT expansionPathogenicrs786200945GRCh37Chr 19, 46273520: 46273522
84DMPKNM_ 004409.4(DMPK): c.*224_ *226[482]NT expansionPathogenicrs786200945GRCh38Chr 19, 45770262: 45770264
85DMPKNM_ 004409.4(DMPK): c.*224_ *226[490]NT expansionPathogenicrs786200945GRCh37Chr 19, 46273520: 46273522
86DMPKNM_ 004409.4(DMPK): c.*224_ *226[50]NT expansionPathogenicrs786200945GRCh37Chr 19, 46273520: 46273522
87DMPKNM_ 004409.4(DMPK): c.*224_ *226[501]NT expansionPathogenicrs786200945GRCh37Chr 19, 46273520: 46273522
88DMPKNM_ 004409.4(DMPK): c.*224_ *226[505]NT expansionPathogenicrs786200945GRCh38Chr 19, 45770262: 45770264
89DMPKNM_ 004409.4(DMPK): c.*224_ *226[508]NT expansionPathogenicrs786200945GRCh38Chr 19, 45770262: 45770264
90DMPKNM_ 004409.4(DMPK): c.*224_ *226[513]NT expansionPathogenicrs786200945GRCh38Chr 19, 45770262: 45770264
91DMPKNM_ 004409.4(DMPK): c.*224_ *226[52]NT expansionPathogenicrs786200945GRCh38Chr 19, 45770262: 45770264
92DMPKNM_ 004409.4(DMPK): c.*224_ *226[53]NT expansionPathogenicrs786200945GRCh38Chr 19, 45770262: 45770264
93DMPKNM_ 004409.4(DMPK): c.*224_ *226[536]NT expansionPathogenicrs786200945GRCh38Chr 19, 45770262: 45770264
94DMPKNM_ 004409.4(DMPK): c.*224_ *226[539]NT expansionPathogenicrs786200945GRCh37Chr 19, 46273520: 46273522
95DMPKNM_ 004409.4(DMPK): c.*224_ *226[54]NT expansionPathogenicrs786200945GRCh38Chr 19, 45770262: 45770264
96DMPKNM_ 004409.4(DMPK): c.*224_ *226[541]NT expansionPathogenicrs786200945GRCh38Chr 19, 45770262: 45770264
97DMPKNM_ 004409.4(DMPK): c.*224_ *226[542]NT expansionPathogenicrs786200945GRCh38Chr 19, 45770262: 45770264
98DMPKNM_ 004409.4(DMPK): c.*224_ *226[56]NT expansionPathogenicrs786200945GRCh38Chr 19, 45770262: 45770264
99DMPKNM_ 004409.4(DMPK): c.*224_ *226[562]NT expansionPathogenicrs786200945GRCh37Chr 19, 46273520: 46273522
100DMPKNM_ 004409.4(DMPK): c.*224_ *226[563]NT expansionPathogenicrs786200945GRCh38Chr 19, 45770262: 45770264
101DMPKNM_ 004409.4(DMPK): c.*224_ *226[583]NT expansionPathogenicrs786200945GRCh38Chr 19, 45770262: 45770264
102DMPKNM_ 004409.4(DMPK): c.*224_ *226[586]NT expansionPathogenicrs786200945GRCh38Chr 19, 45770262: 45770264
103DMPKNM_ 004409.4(DMPK): c.*224_ *226[59]NT expansionPathogenicrs786200945GRCh38Chr 19, 45770262: 45770264
104DMPKNM_ 004409.4(DMPK): c.*224_ *226[593]NT expansionPathogenicrs786200945GRCh38Chr 19, 45770262: 45770264
105DMPKNM_ 004409.4(DMPK): c.*224_ *226[594]NT expansionPathogenicrs786200945GRCh37Chr 19, 46273520: 46273522
106DMPKNM_ 004409.4(DMPK): c.*224_ *226[60]NT expansionPathogenicrs786200945GRCh37Chr 19, 46273520: 46273522
107DMPKNM_ 004409.4(DMPK): c.*224_ *226[609]NT expansionPathogenicrs786200945GRCh38Chr 19, 45770262: 45770264
108DMPKNM_ 004409.4(DMPK): c.*224_ *226[614]NT expansionPathogenicrs786200945GRCh38Chr 19, 45770262: 45770264
109DMPKNM_ 004409.4(DMPK): c.*224_ *226[62]NT expansionPathogenicrs786200945GRCh38Chr 19, 45770262: 45770264
110DMPKNM_ 004409.4(DMPK): c.*224_ *226[64]NT expansionPathogenicrs786200945GRCh38Chr 19, 45770262: 45770264
111DMPKNM_ 004409.4(DMPK): c.*224_ *226[640]NT expansionPathogenicrs786200945GRCh38Chr 19, 45770262: 45770264
112DMPKNM_ 004409.4(DMPK): c.*224_ *226[65]NT expansionPathogenicrs786200945GRCh38Chr 19, 45770262: 45770264
113DMPKNM_ 004409.4(DMPK): c.*224_ *226[666]NT expansionPathogenicrs786200945GRCh38Chr 19, 45770262: 45770264
114DMPKNM_ 004409.4(DMPK): c.*224_ *226[68]NT expansionPathogenicrs786200945GRCh37Chr 19, 46273520: 46273522
115DMPKNM_ 004409.4(DMPK): c.*224_ *226[688]NT expansionPathogenicrs786200945GRCh38Chr 19, 45770262: 45770264
116DMPKNM_ 004409.4(DMPK): c.*224_ *226[69]NT expansionPathogenicrs786200945GRCh38Chr 19, 45770262: 45770264
117DMPKNM_ 004409.4(DMPK): c.*224_ *226[71]NT expansionPathogenicrs786200945GRCh38Chr 19, 45770262: 45770264
118DMPKNM_ 004409.4(DMPK): c.*224_ *226[72]NT expansionPathogenicrs786200945GRCh38Chr 19, 45770262: 45770264
119DMPKNM_ 004409.4(DMPK): c.*224_ *226[721]NT expansionPathogenicrs786200945GRCh38Chr 19, 45770262: 45770264
120DMPKNM_ 004409.4(DMPK): c.*224_ *226[74]NT expansionPathogenicrs786200945GRCh38Chr 19, 45770262: 45770264
121DMPKNM_ 004409.4(DMPK): c.*224_ *226[75]NT expansionPathogenicrs786200945GRCh38Chr 19, 45770262: 45770264
122DMPKNM_ 004409.4(DMPK): c.*224_ *226[758]NT expansionPathogenicrs786200945GRCh38Chr 19, 45770262: 45770264
123DMPKNM_ 004409.4(DMPK): c.*224_ *226[76]NT expansionPathogenicrs786200945GRCh38Chr 19, 45770262: 45770264
124DMPKNM_ 004409.4(DMPK): c.*224_ *226[780]NT expansionPathogenicrs786200945GRCh37Chr 19, 46273520: 46273522
125DMPKNM_ 004409.4(DMPK): c.*224_ *226[80]NT expansionPathogenicrs786200945GRCh37Chr 19, 46273520: 46273522
126DMPKNM_ 004409.4(DMPK): c.*224_ *226[814]NT expansionPathogenicrs786200945GRCh38Chr 19, 45770262: 45770264
127DMPKNM_ 004409.4(DMPK): c.*224_ *226[816]NT expansionPathogenicrs786200945GRCh38Chr 19, 45770262: 45770264
128DMPKNM_ 004409.4(DMPK): c.*224_ *226[82]NT expansionPathogenicrs786200945GRCh38Chr 19, 45770262: 45770264
129DMPKNM_ 004409.4(DMPK): c.*224_ *226[823]NT expansionPathogenicrs786200945GRCh38Chr 19, 45770262: 45770264
130DMPKNM_ 004409.4(DMPK): c.*224_ *226[83]NT expansionPathogenicrs786200945GRCh38Chr 19, 45770262: 45770264
131DMPKNM_ 004409.4(DMPK): c.*224_ *226[84]NT expansionPathogenicrs786200945GRCh37Chr 19, 46273520: 46273522
132DMPKNM_ 004409.4(DMPK): c.*224_ *226[88]NT expansionPathogenicrs786200945GRCh37Chr 19, 46273520: 46273522
133DMPKNM_ 004409.4(DMPK): c.*224_ *226[887]NT expansionPathogenicrs786200945GRCh38Chr 19, 45770262: 45770264
134DMPKNM_ 004409.4(DMPK): c.*224_ *226[92]NT expansionPathogenicrs786200945GRCh37Chr 19, 46273520: 46273522
135DMPKNM_ 004409.4(DMPK): c.*224_ *226[93]NT expansionPathogenicrs786200945GRCh38Chr 19, 45770262: 45770264
136DMPKNM_ 004409.4(DMPK): c.*224_ *226[96]NT expansionPathogenicrs786200945GRCh38Chr 19, 45770262: 45770264
137DMPKNM_ 004409.4(DMPK): c.*224_ *226[98]NT expansionPathogenicrs786200945GRCh38Chr 19, 45770262: 45770264
138DMPKNM_ 001081563.2: c.*224_ *226CTG[30]CCG[2]CTG[2]CCG[1]CTG[105]NT expansionPathogenic
139DMPKNM_ 001081563.2: c.*224_ *226CTG[28]CCG[2]CTG[2]CCG[1]CTG[88]NT expansionPathogenic
140DMPKNM_ 001081560.2(DMPK): c.*224_ *226CTG(51_ ?)NT expansionPathogenicGRCh37Chr 19, 46273463: 46273465
141DMPKNM_ 001081563.1: c.*224_ 226CTG(50-?)undetermined variantPathogenic

Expression for genes affiliated with Myotonic Dystrophy 1

About this section
LifeMap Discovery
Genes differentially expressed in tissues of Myotonic Dystrophy 1 patients vs. healthy controls: 35 (show all 15)
id Gene Description Tissue Up/Dn Fold Change (log2) P value
1MAFFv-maf avian musculoaponeurotic fibrosarcoma oncogene homolog FSkeletal Muscle-4.360.001
2COL21A1collagen, type XXI, alpha 1Skeletal Muscle+3.860.000
3COL4A3collagen, type IV, alpha 3 (Goodpasture antigen)Skeletal Muscle+3.810.000
4RARRES1retinoic acid receptor responder (tazarotene induced) 1Skeletal Muscle-3.530.003
5NNMTnicotinamide N-methyltransferaseSkeletal Muscle-3.500.000
6PRPF38Bpre-mRNA processing factor 38BSkeletal Muscle+3.480.000
7NEBnebulinSkeletal Muscle+3.420.000
8RIF1replication timing regulatory factor 1Skeletal Muscle+3.330.000
9SPXspexin hormoneSkeletal Muscle+3.310.001
10SCD5stearoyl-CoA desaturase 5Skeletal Muscle+3.200.000
11AQP4aquaporin 4Skeletal Muscle+3.190.001
12CHI3L1chitinase 3-like 1 (cartilage glycoprotein-39)Skeletal Muscle-3.090.009
13SLC39A14solute carrier family 39 (zinc transporter), member 14Skeletal Muscle-3.070.003
14GOLGA8Agolgin A8 family, member ASkeletal Muscle+3.030.000
15COL3A1collagen, type III, alpha 1Skeletal Muscle+3.020.001

Search GEO for disease gene expression data for Myotonic Dystrophy 1.

Pathways for genes affiliated with Myotonic Dystrophy 1

About this section

GO Terms for genes affiliated with Myotonic Dystrophy 1

About this section

Cellular components related to Myotonic Dystrophy 1 according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1nuclear outer membraneGO:000564010.3DHCR7, DMPK
2sarcoplasmic reticulum membraneGO:00330179.6ATP2A1, DMPK

Biological processes related to Myotonic Dystrophy 1 according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1histone H3-T6 phosphorylationGO:003540810.4PRKCA, PRKCB
2cholesterol biosynthetic processGO:000669510.3CNBP, DHCR7
3peptidyl-serine phosphorylationGO:001810510.0DMPK, PRKCA, PRKCB
4regulation of RNA splicingGO:00434849.8CELF1, MBNL1

Molecular functions related to Myotonic Dystrophy 1 according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1calcium-dependent protein kinase C activityGO:000469810.2PRKCA, PRKCB
2histone kinase activity (H3-T6 specific)GO:003540310.2PRKCA, PRKCB
3protein kinase C activityGO:00046979.9PRKCA, PRKCB

Sources for Myotonic Dystrophy 1

About this section
2CDC
6CNVD
10DGIdb
15ExPASy
16FDA
17FMA
27GTR
28HGMD
29HMDB
30ICD10
31ICD10 via Orphanet
32ICD9CM
33IUPHAR
34KEGG
37MedGen
39MeSH
40MESH via Orphanet
41MGI
44NCI
45NCIt
46NDF-RT
49NINDS
50Novoseek
52OMIM
53OMIM via Orphanet
57PubMed
58QIAGEN
63SNOMED-CT via Orphanet
67Tumor Gene Family of Databases
68UMLS
69UMLS via Orphanet